Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 4 institutions in 3 countries.
Sonja KleeschulteDepartment of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Düsseldorf, Germany.
Vivien FischingerInstitute for Pharmacology and Clinical Pharmacology, University Hospital Düsseldorf, Düsseldorf, Germany.
Lisa ÖhlkeInstitute for Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Duisburg, Germany.
Johannes BodeDepartment of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Düsseldorf, Germany.
Markus KamlerDepartment of Thoracic and Cardiovascular Surgery, University Hospital Essen, Essen, Germany.
Dobromir DobrevInstitute for Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Duisburg, Germany.
Maria GrandochInstitute for Translational Pharmacology and CARID Cardiovascular Research Institute Düsseldorf, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Anke C FenderInstitute for Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Duisburg, Germany. anke.fender@uk-essen.de.ORCID http://orcid.org/0000-0003-3965-6165
Düsseldorf University Hospital · DEWest German Heart and Vascular Center Essen · DEBaylor College of Medicine · USEssen University Hospital · DE
Funding
Ryanodine receptor regulation in post-operative atrial fibrillationR01HL089598 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI WEHRENS, XANDER H.T. · 2007 to 2022
$6.5M
The Role of Inflammasome in the Pathogenesis of Atrial FibrillationR01HL136389 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Na Li · 2017 to 2026
$5.6M
Sex-specific arrhythmogenic mechanisms of atrial fibrillationR01HL131517 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Eleonora Grandi · 2016 to 2026
$5.0M
Cardiac fibroblast inflammasome and atrial myopathyR01HL163277 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI LI, NA · 2022 to 2025
$2.8M
Role of Nucleoside-Diphosphate Kinase Signaling in Atrial FibrillationR01HL160992 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Xander H.T. Wehrens · 2023 to 2026
$2.1M
Deutsche Forschungsgemeinschaft RO 3921/2-1; FE 1365/4-1; CRC 1116 "Master switches in cardiac ischemia" TP b10Ernst und Berta Grimmke Stiftung 3/09European Union MAESTRIA 965286NHLBI NIH HHS R01 HL089598NHLBI NIH HHS R01 HL131517NHLBI NIH HHS R01 HL136389NHLBI NIH HHS R01 HL160992NHLBI NIH HHS R01 HL163277NIH HHS R01-HL131517, R01-HL136389, R01-HL089598, R01HL163277, R01HL160992
6 · The paper itself
Abstract
Thrombin inhibition suppresses adiposity, WAT inflammation and metabolic dysfunction in mice. Protease-activated receptor (PAR)1 does not account for thrombin-driven obesity, so we explored the culprit role of PAR4 in this context. Male WT and PAR-4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The thrombin receptor PAR4 supports visceral adipose tissue inflammation. · full record | OpenQuestion